Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Virulizin

    Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
    |November 1, 2002
    PubMed
    Summary
    This summary is machine-generated.

    Virulizin, a biological response modifier, shows promise in treating pancreatic cancer by improving survival and quality of life. Further clinical trials are ongoing to evaluate its efficacy in various advanced cancers.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same journal

    Gene Therapy Strategies for Uveal Melanoma: Adeno-associated Virus Delivery Challenges and Translational Opportunities.

    BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
    Same journal

    Review of Quality Attributes and Analytical Methods Used for Comparative Analytical Assessment of Monoclonal Antibodies as Part of Successful Biosimilar Approvals in the United States and European Union.

    BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
    Same journal

    Impact of Repeated Antigen Exposure on Humoral Tolerance: Antidrug Antibodies After Single-Dose Versus Multi-dose Adalimumab.

    BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
    Same journal

    An Overview and Trend Analysis of Biosimilar Approvals in China.

    BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
    Same journal

    Monoclonal Antibodies Targeting Bacterial Infections: A Broad Review of the Field.

    BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
    Same journal

    mRNA Vaccines for Influenza: Hope for a Universal Vaccine?

    BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
    See all related articles

    Area of Science:

    • Immunology and Oncology
    • Pharmacology and Drug Development

    Background:

    • Virulizin is a biological response modifier derived from bovine reticuloendothelial tissue.
    • It functions by activating macrophages and is under development for various cancers.

    Purpose of the Study:

    • To evaluate Virulizin's efficacy and safety in treating advanced pancreatic cancer.
    • To assess Virulizin as a first- and second-line treatment in combination with standard chemotherapies.

    Main Methods:

    • Phase III clinical trial comparing Virulizin + gemcitabine versus gemcitabine alone for first-line therapy.
    • Second-line therapy assessed Virulizin + fluorouracil versus fluorouracil alone in patients resistant to gemcitabine.

    Main Results:

    • Meta-analysis of Phase I/II studies indicated Virulizin improved survival and quality of life in pancreatic cancer patients.

    Related Experiment Videos

  • Orphan drug and fast track designations were granted by the US FDA for pancreatic cancer treatment.

    • Conclusions:

    • Virulizin demonstrates potential as a therapeutic agent for advanced pancreatic cancer.
    • Ongoing studies and preclinical research suggest broader applications in other malignancies.